Since the commercial launch of its technology last year, the firm has been validating it in studies with academic groups and pharmaceutical companies.
Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
Guardant's test will be used to detect mutations associated with acquired resistance to EGFR-inhibiting therapies and to guide further treatment strategies in a study of 600 patients.
U of Michigan Cancer Group Lands $63M from NCI
The funding will support the creation of biorepositories, biomarker discovery and validation, and personalized cancer therapeutic clinical trials.
CancerGen's First Comparative Effectiveness Trial to Study Oncotype DX in Node-Positive Breast Cancer
The Center for Comparative Effectiveness Research in Cancer Genomics expects its first clinical trial, which is investigating the predictive value of Genomic Health's Oncotype Dx in node-positive breast cancer patients, to serve as a model for future comparative effectiveness studies looking at genomic technologies in cancer.